Condition
Advanced HCC
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (1)
P 3 (1)
Trial Status
Unknown2
Completed2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06818097CompletedPrimary
Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC
NCT05906524Phase 1UnknownPrimary
KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
NCT05831969Phase 2UnknownPrimary
Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC
NCT04601610Phase 1TerminatedPrimary
KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma
NCT00396682Phase 3CompletedPrimary
Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular Carcinoma
Showing all 5 trials